Calcifying Aponeurotic Fibroma

Calcifying aponeurotic fibroma (CAF) is a rare benign fibroblastic soft-tissue tumour arising in the aponeuroses and deep fascia of the distal extremities, characteristically in the palm, wrist, sole and ankle of children and adolescents. Keasbey described it in 1953 as juvenile aponeurotic fibroma, and it is still occasionally called Keasbey tumour.

It occupies a distinctive niche: benign histology, infiltrative growth, high local recurrence, and no metastatic potential whatsoever. The clinical challenge is therefore not oncological control but correct diagnosis and restrained surgery, because the two ways to harm a child with this lesion are to mistake it for a sarcoma and over-treat, or to mistake a sarcoma for it and under-treat.

Local aggressiveness is not malignancy. Examiners ask about this lesion precisely because it forces the candidate to separate the two, and conflating them is the commonest error. The lesion grows along fascial planes and around tendons and nerves rather than expanding as an encapsulated ball, so a "shelled out" specimen almost always leaves microscopic disease behind. That is why recurrence rates of around 50% are quoted, and why they are higher in younger children with more diffuse lesions.

Know where that number comes from before you quote it at a parent. The primary series behind it is Fetsch and Miettinen, in whom five of the ten patients with any follow-up recurred - a denominator of ten, not of the twenty-two reported - and figures across series range roughly from a third to two-thirds. "About half" is a convention that has held up across small series, not a measured rate, and the honest sentence is it comes back in roughly half of children.

It has no metastatic capacity. There are no convincing reports of metastasis. Rare reports of sarcomatous transformation exist in the literature but are anecdotal, contested, and should be treated with scepticism rather than used to justify aggressive treatment.

So the operation is a marginal excision, and a recurrence is re-excised, not escalated. Radical resection, amputation and radiotherapy have no place. Radiotherapy in particular is actively harmful in a growing child, carrying risks of growth arrest, contracture and secondary malignancy for a lesion that will never spread.

The mirror-image error is more dangerous. In an adolescent with a hand or foot mass, synovial sarcoma and epithelioid sarcoma must be excluded. Both can present as a small, slow-growing, apparently innocuous mass, and synovial sarcoma calcifies in a substantial minority. Imaging before excision, and a planned biopsy where there is any doubt, is what prevents an unplanned excision of a sarcoma.

How rare. It is an uncommon lesion even in specialist soft-tissue tumour practice, and most orthopaedic surgeons will see very few in a career.

Age. Children and adolescents, with the great majority presenting under 20 years, in two recognised patterns. Presentation in adults is described but distinctly uncommon, and should prompt particular care over the differential diagnosis.

• Under about 5 years: lesions tend to be more diffuse and infiltrative, with sparse or absent calcification. These are the ones most often misdiagnosed, most likely to recur, and the ones to keep under closer surveillance.
• Around 8 to 15 years: lesions tend to be more nodular and better defined, with more conspicuous calcification and well-formed chondroid nodules - the classic radiographic and histological appearance.

Sex and cause. A male predominance is consistently reported, in the order of 2 to 1. There is no known inherited predisposition, no association with a syndrome, and no established environmental or traumatic cause; trauma is frequently reported by families but is almost certainly coincidental.

Maturation with age is a recognised phenomenon: the older the child, the more calcified, more nodular and better circumscribed the lesion tends to be, which is why the radiographic appearance is age-dependent.

Where It Occurs

What drives it. The lesion is a clonal fibroblastic neoplasm, not a reactive or post-traumatic process. Recurrent FN1-EGF gene fusions join it to a small group of tumours characterised by fibronectin (FN1) fusions, a group that also includes some cartilaginous and fibro-osseous lesions with a tendency to matrix calcification. That is a satisfying molecular explanation for the chondroid, calcifying phenotype.

The chondroid nodules are best understood as metaplastic cartilaginous differentiation within a fibroblastic proliferation, with dystrophic calcification developing centrally in those nodules and progressive ossification occasionally seen.

The infiltrative growth along fascial planes is intrinsic to the lesion and is the biological basis of its recurrence rate. It is not a consequence of inadequate surgery, although inadequate surgery makes it worse.

Macroscopic Appearance

Gritty, grey-white and unencapsulated. The mass is firm to hard and poorly circumscribed, with no true capsule, blending into the surrounding fascia, fat and tendon, and gritty on cutting where calcification is present.

View larger

Microscopic Appearance - the Diagnostic Triad

1. An infiltrative, moderately cellular fibroblastic proliferation of bland spindle and stellate cells in a collagenous stroma, extending between fat lobules, along fascial septa and around tendons and nerves. The cells are cytologically bland - no significant pleomorphism, no atypia, and mitoses are rare and never atypical.
2. Chondroid nodules - the diagnostic feature. Rounded nodules of cartilaginous or chondroid matrix containing central dystrophic calcification, sometimes progressing to ossification.
3. Palisading of rounded, epithelioid, chondrocyte-like cells at the periphery of the calcified nodules - the cells line up radially around each nodule. This palisade is the single most characteristic microscopic feature.

Additional features. Osteoclast-like multinucleated giant cells may be scattered around the calcified foci. In very young children the lesion is often more diffuse, more cellular and less calcified, so the chondroid nodules may be few or absent - making the diagnosis considerably harder and increasing the chance of misdiagnosis as an infantile fibromatosis or fibrosarcoma.

What must not be there. No necrosis, no vascular invasion, no high-grade areas. Their presence means the diagnosis is wrong.

View larger

View larger

View larger

View larger

Immunohistochemistry

Morphology makes the diagnosis; the panel is read against the mimics.

• Smooth muscle actin (SMA): variable, often patchy positivity in the spindle cell component (myofibroblastic differentiation)
• S100: may be positive in the chondroid areas, reflecting cartilaginous differentiation - a trap if over-interpreted as a nerve sheath tumour
• Beta-catenin: no nuclear staining, which is the discriminator against desmoid-type fibromatosis, where nuclear accumulation is characteristic
• Cytokeratin, EMA and CD34: negative, helping exclude epithelioid sarcoma and some other mimics
• INI1 (SMARCB1): retained; loss is the hallmark of epithelioid sarcoma, a critical differential in the hand of an adolescent
• TLE1: negative; diffuse strong positivity supports synovial sarcoma
• Desmin and myogenin: negative, excluding rhabdomyosarcoma

Molecular Findings

• Recurrent FN1-EGF gene fusions have been described; where available, demonstration of an FN1 rearrangement supports the diagnosis in a histologically difficult or unusually sited case
• No SS18 (SYT) rearrangement - its presence indicates synovial sarcoma
• No CTNNB1 or APC alteration of the desmoid type
• No ETV6-NTRK3 fusion - its presence indicates infantile fibrosarcoma

The Differential Diagnosis

Learn it as a table. Age and site narrow it, the chondroid nodules with peripheral palisading settle it against the fibromatoses, and molecular testing rather than impression settles it against synovial sarcoma.

Classification

There is no staging and no grading system, because there is no malignant potential. The only variables that matter clinically are the age pattern set out above, the margin achieved, and whether function can be preserved.

• A marginal or wide excision makes residual microscopic disease less likely and carries the lower - though still real - recurrence risk, but never sacrifice a tendon, nerve or neurovascular bundle to obtain it
• An intralesional or piecemeal excision leaves microscopic and often macroscopic disease behind and a high recurrence risk; it is acceptable as a deliberate choice when a wider margin would cost function, and not acceptable as the result of poor planning

The typical story. A painless, slowly enlarging, firm lump in the palm, sole, wrist or ankle of a child, often noticed incidentally by a parent or during an unrelated examination. Because it does not hurt, the duration before presentation is frequently months to years.

On examination it is firm to hard, poorly circumscribed and fixed to the underlying fascia or tendon, moving with that structure rather than independently of it, and the overlying skin is normal and freely mobile. Size at presentation is usually 1 to 3 cm; lesions larger than about 3 cm are less common and should raise the threshold for a formal diagnostic work-up.

Function is usually normal. Where the flexor tendon sheath is involved there may be mild loss of finger flexion or a sensation of tightness, but frank contracture is unusual. Multiple lesions in the same limb are described but uncommon.

Symptoms that should make you pause. Any of these shifts the emphasis toward excluding a sarcoma:

• Pain or rapid growth
• Size greater than about 5 cm
• A deep location beneath the fascia in an unusual site
• Neurological deficit
• A mass in an adolescent adjacent to a joint

Clinical Assessment

Surgical Principles

Approach. A longitudinal incision in the palm or sole, placed along the relevant crease or a standard extensile line and oriented so that it can be extended and, if necessary, incorporated into a wider resection. Avoid transverse incisions that cross flexor creases, and avoid incisions on weight-bearing plantar surfaces where possible.

Tourniquet and magnification. Use both in the hand. The lesion infiltrates fascia and can be intimately related to digital nerves, and loupe magnification materially improves the chance of preserving them.

Extent. Excise the lesion together with the involved aponeurosis, since that is its tissue of origin. Removing a nodule and leaving the surrounding infiltrated fascia guarantees recurrence.

What to preserve at all costs. The digital nerves and their branches, the digital neurovascular bundles, the flexor tendons with their sheaths and pulleys, and the plantar digital nerves and vessels. It is entirely correct to dissect the lesion off these structures and accept a positive margin there; a functional hand with a recurrence is a better outcome than a stiff, insensate hand without one.

Frozen section has limited value here, and the diagnosis is best made on formal histology with immunohistochemistry.

Reconstruction is rarely needed. Where an extensive palmar fascial excision leaves a defect, a full-thickness graft or local flap may be required - and needing extensive reconstruction should raise the question of whether the resection was more aggressive than the diagnosis justified.

What not to do. Amputation, compartmental or radical resection, adjuvant radiotherapy, or chemotherapy: none is indicated for a benign lesion with no metastatic potential.

Management of Recurrence

Expect it. Most recurrences present within 3 years of excision, and the risk is higher after an incomplete excision.

Re-excise marginally, with the same functional priorities as the first operation. A second recurrence is managed the same way.

Reconfirm the histology on the recurrence specimen. That is not because malignant transformation is expected - it is not - but because a persistent or unusual lesion is an opportunity to make certain the original diagnosis was right.

Observation instead is reasonable for a small, asymptomatic recurrence in a functionally critical site, in a child in whom repeated dissection would cost more than the lesion does.

Multiple recurrences are not an indication to escalate. They are an indication to be sure of the diagnosis and to accept a functionally driven, deliberately conservative strategy.

View larger

View larger

Prognosis

Excellent. There is no established capacity for malignant transformation, and local recurrence is the only meaningful adverse event.

Function is usually excellent provided the surgery is restrained. Where function is lost, it is far more often because of over-aggressive resection or nerve injury than because of the tumour.

Lesions may become better circumscribed and more calcified with age, and there are reports of recurrences behaving in a more nodular and more easily excised fashion in older children.

Follow-Up Strategy

What to Tell the Family

The sentence that does the work is short: this is a benign lump; it can come back in the same place, and if it does we simply take it out again; it will not spread anywhere else and it will not become cancer. Add that it grows into the surrounding tissue rather than sitting in a capsule, which is why it can come back, and that we will deliberately not chase every last cell if that would mean damaging a nerve or a tendon, because the hand or foot matters more than the margin. Then teach the family and, as they grow, the patient, to report a new or enlarging lump at any point.

Related pages. The mimics that must be excluded before any excision: Synovial Sarcoma shares the age group, the distal-extremity site and the calcification, and is the single most important alternative diagnosis; Epithelioid Sarcoma classically arises in the hand and forearm of adolescents and young adults and can look innocuous for years. Soft Tissue Masses and Sarcoma Referral and Biopsy Principles and Techniques set out why the biopsy is planned and its track placed so it can be excised — an unplanned excision is the avoidable harm on this page. The other infiltrative fibroblastic lesions: Desmoid Tumour is the lesion beta-catenin is used to separate this one from, and Dupuytren Disease and Plantar Fibromatosis are the palmar and plantar fibromatoses that occupy the same aponeuroses in adults. Other causes of a calcified soft-tissue mass: Myositis Ossificans and Tumoral Calcinosis, with Synovial Chondromatosis and Enchondroma for the chondroid differential the palisaded chondroid foci can suggest. Soft Tissue Mass of the Foot is the regional approach for the plantar presentation.

Global Framing and Epidemiology

• Calcifying aponeurotic fibroma is rare everywhere and no population predilection has been established. Reported series come from specialist soft-tissue pathology referral centres in Europe, North America and Asia with broadly consistent findings on age, site, sex and recurrence.
• Because it is rare, most published evidence is level 4 retrospective series and case reports. There are no randomised trials and there never will be. Practice is therefore built on consistent observations across small series: benign behaviour, high local recurrence, no metastasis.
• No registry captures this lesion specifically. National and regional sarcoma registries and multidisciplinary team datasets capture it incidentally as a benign diagnosis referred for assessment of an indeterminate soft-tissue mass, which is in fact the appropriate route for most of these lesions.

Side-by-Side Guidance

Areas of Genuine Uncertainty

• The true recurrence rate. Figures ranging from roughly a third to two-thirds are reported. Series are small, margin definitions differ, and follow-up duration varies, so the commonly quoted "around 50%" is best treated as an order of magnitude.
• Whether malignant transformation genuinely occurs. A handful of reports describe sarcomatous change, but they are contested and may reflect misdiagnosis of the original lesion. The safest position is that it should not influence management.
• Optimal margin. Whether a deliberately wider excision meaningfully reduces recurrence, and whether any reduction would justify the functional cost in a hand or foot, has not been tested.
• Whether observation is an equivalent strategy for a small asymptomatic lesion or a small asymptomatic recurrence in a functionally critical site. It is widely practised and biologically defensible, but unstudied.
• The role of molecular testing in routine practice. FN1 rearrangement testing is available in specialist centres and helpful in difficult cases, but its cost-effectiveness in a lesion that is usually diagnosable on morphology is unclear.
• Optimal surveillance interval and duration. No comparative data exist; the commonly used schedule of 6-monthly review for 2 to 3 years then annually to skeletal maturity is pragmatic rather than evidence-based.

High- versus Limited-Resource Practice

• Well-resourced settings: plain radiographs and contrast-enhanced MRI, specialist soft-tissue pathology with a full immunohistochemistry panel and molecular testing, multidisciplinary team discussion before surgery, planned biopsy, hand or foot surgical expertise, and hand therapy after excision.
• Limited-resource settings: the most valuable single investigation is the one most widely available - a plain radiograph, which in a child with a firm painless palmar or plantar mass can strongly suggest the diagnosis when it shows fine stippled calcification. Ultrasound is an excellent and underused tool for both assessment and surveillance, avoids sedation, and needs no contrast. Where MRI and molecular testing are unavailable, the safeguards that matter most are clinical discipline - do not perform an unplanned excision of a mass in an adolescent, particularly near a joint; take a proper biopsy through an incision that can be re-excised; and refer or seek pathology review where the diagnosis is uncertain.
• Everywhere: the highest-value interventions are restraint and honest counselling. Do not over-resect a benign lesion; do not irradiate it; do not amputate for a recurrence; and make sure the family understands before surgery that recurrence is likely and harmless.